Experimental drug BOLD-100 paired with chemotherapy targets Hard-to-Treat sarcomas
NCT ID NCT07027423
First seen Dec 10, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This early-phase trial tests a new drug called BOLD-100 combined with the chemotherapy doxorubicin in 32 people with advanced soft tissue sarcomas that cannot be removed by surgery or have spread. The main goals are to find the safest dose and check for side effects. Participants receive the drugs intravenously over several cycles, and doctors will monitor tumor response with scans every 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UHN- Princess Margaret Cancer Center
Toronto, Ontario, M5G 1Z5, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BOLD-100 (a ruthenium-based drug) combined with doxorubicin (chemotherapy)
What this could lead to
If successful, this could lead to a new combination treatment that slows or shrinks advanced soft tissue sarcomas, offering an option for patients who have not had prior therapy.
What could go wrong
This is a very early Phase 1b trial with only 32 people, focused on safety and dosing—not yet proven to work. The combination may cause significant side effects, and results may not apply to all sarcoma types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.